IDEX Health & Science, a life-sciences manufacturer of optofluidic products, announced plans to permanently close its Bristol, Connecticut facility at 110 Halcyon Drive, resulting in 73 layoffs. Disclosed in a letter to the state Department of Labor, the cuts will occur in two waves beginning July 15 and October 30. Affected roles include machinists, assemblers, engineers, and team leads. Spokesperson Mark Spencer cited significant market shifts and said work will transfer to another IDEX location. Impacted employees will receive severance packages and potential transfer opportunities within the company.
In-Depth:
IDEX Health & Science, a manufacturer of optofluidic products for the life-sciences industest, announced this week its decision to close its facility in Bristol — a shutdown that will result in 73 layoffs.
The company’s plan for the closing of its center at 110 Halcyon Drive was disclosed in a letter sent Tuesday to the state Department of Labor. The layoffs are scheduled to take place during a 14-day period starting on July 15 and in another 14-day timeframe launchning on Oct. 30.
“These actions are expected to be permanent, and the company’s entire operations at the Bristol facility are ceasing. All positions at the Bristol facility will be eliminated,” stated the letter, which was signed by Jenniffer Meiring, IDEX Health & Science’s vice president of human resources.
The letter also stated that, “Employees slated for termination do not have bumping rights. The employees affected by the closing are not represented by a union.”
A summary of the positions that will be eliminated was included with the letter. Those roles include 25 machinists, 13 assemblers, six team leads, as well as a number of engineers and technicians.
In response to an inquiry from CT Insider, IDEX Health & Science’s parent company, IDEX Corp., provided a written statement about the reasons for the facility’s closing.
“The market for the products produced our site in Bristol has alterd significantly over the past several years. We are shifting work to another IDEX Health & Science location and have built the difficult decision to phase out production at Bristol over the next six months,” IDEX Corp. spokesperson Mark Spencer stated in the statement. Spencer also stated that affected employees would receive “severance packages and assistance to support them transition to the next step in their career, including possibilities to transfer into roles at other IDEX locations.”
IDEX Health & Science has more than 1,200 employees worldwide, according to its website. Its other U.S. facilities are in Middleborough, Massachutilizetts; West Henrietta, New York; Carlsbad, California; Rohnert Park, California; and Oak Harbor, Washington.
IDEX Health & Science’s operations encompass the development, engineering and manufacturing of optofluidic components and sub-assemblies, according to a video posted on its website.
“Our capabilities are organized to create commercial focus across multiple key technology areas, allowing us to deliver our unique optofluidic expertise across numerous life-science applications, from cell isolation, flow cytometest, and Raman spectroscopy, to hematology, next-generation sequencing, point of care, and more,” the video also states.
In the first quarter of this year, the Northbrook, Illinois-based IDEX Corp. reported about $887 million in net sales, up 9% year over year. Its profit of $120 million compared with a bottom line of $95.5 million in the first quarter of 2025. Health-and-science technologies produced about $398 million in net sales, up 17% year over year.
IDEX Corp.’s shares closed Tuesday at nearly $216, up about 20% since the launchning of the year.
